Clinical trials: Systemic Sclerosis Pulmonary
Pulmonary Disease, Pulmonary Emphysema
In Vivo Endomicroscopic Description of Pulmonary Microcirculation in Systemic Sclerosis and Emphysema Patients
Systemic sclerosis (SSc) is a generalized disorder of connective tissue, arterioles and microvessels, characterized by the occurrence of fibrosis and vascular obliteration phenomena.
- Trial name
- MiPECSE (NCT02556697)
- Testing
- Bronchoscopy with in vivo confocal endomicroscopy
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Rouen
Lung Diseases, Pulmonary Fibrosis
Scleroderma Lung Disease
To evaluate the efficacy and safety of cyclophosphamide versus placebo for the prevention and progression of symptomatic pulmonary disease in patients with systemic sclerosis.
- Conditions
- Lung Diseases, Pulmonary Fibrosis, Systemic Scleroderma, Scleroderma, Systemic
- Trial name
- SLS (NCT00004563)
- Testing
- Cyclophosphamide
- Volunteers
- 158 people
- Sponsor
- The University of Texas Health Science Center, Houston
Connective Tissue Diseases
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
This is an open label extension (OLE) study of an ongoing randomized controlled parent clinical studies 218224 (NCT05878717) and 221672 (NCT06572384) which aim to assess the efficacy and safety of belimumab on reducing the…
- Trial name
- NCT06716606
- Testing
- Belimumab
- Where
- 41 sites in United States, Argentina and 9 more
- Volunteers
- 514 people
- Sponsor
- GlaxoSmithKline
Scleroderma
MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients
Assessment of pulmonary fibrosis is currently based on high-resolution CT (HRCT) and pulmonary function tests (PFT) such as forced vital capacity, (FVC) and carbon monoxide diffusion (DLCO).
- Trial name
- IRMSCLERO (NCT03207997)
- Testing
- unenhanced MR sequences
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis, Diaphragm Defect
Muscular Respiratory Involvement and Systemic Sclerosis
Dyspnea in systemic sclerosis (ScS) constitute a major factor of functional disability. Intensity of dyspnea is sometimes discordant with objectives data from cardiopulmonary involvements, suggesting unknown additional factors.
- Conditions
- Systemic Sclerosis, Diaphragm Defect, Respiratory Insufficiency, Pulmonary Function Test
- Trial name
- SIROCO (NCT04118725)
- Testing
- Pulmonary function test
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Poitiers University Hospital
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis
This protocol is of a systematic review for risk factors of pulmonary arterial hypertension in systemic sclerosis.
- Trial name
- NCT03889509
- Where
- Canada
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Pirfenidone, Connective Tissue Diseases
Efficacy and Safety of Pirfenidone in CTD-ILD
A single-center randomized controlled study will be used to observe the efficacy and safety of pirfenidone on CTD-ILD patients for 24 months. The main research endpoints is the lung function (FVC) at 6 months.
- Conditions
- Pirfenidone, Connective Tissue Diseases, Interstitial Lung Disease
- Trial name
- NCT05505409
- Testing
- Pirfenidone, glucocorticoid and immunosuppressant
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qilu Hospital of Shandong University
Systemic Sclerosis (SSc), Pulmonary Arterial Hypertension (PAH)
Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis
The goal of this observational pilot trial is to evaluate the feasibility of home monitoring for patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH).
- Conditions
- Systemic Sclerosis (SSc), Pulmonary Arterial Hypertension (PAH), Home Monitoring Follow-up
- Trial name
- Nor-SScCare (NCT06865118)
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Systemic Sclerosis, Pulmonary Hypertension
Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc)
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package- the Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa…
- Trial name
- NCT02278445
- Testing
- Doppler ultrasound, Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)
- Where
- Israel
- Sponsor
- Echosense Ltd.
Systemic Sclerosis in Adults
Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease
The purpose of this study is to determine whether Rituximab is safe and effective as a maintenance strategy in individuals with stabilized systemic sclerosis in adults.
- Trial name
- MAINRITSyS (NCT07827742)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis With and Without Interstitial Lung Disease
A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants with Systemic Sclerosis (SSc) following multiple doses.
- Trial name
- NCT04948554
- Testing
- MK-2225
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 5 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Systemic Sclerosis
Chest CT Biomarkers as Prognostic Predictors in SSc-ILD
The goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ILD progression, vasculopathy development, and survival…
- Trial name
- NCT06472362
- Testing
- HRCT biomarkers
- Where
- 7 sites in France, Germany and 2 more
- Volunteers
- 1,000 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Scleroderma, Scleroderma, Systemic
Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program
Contagious disease outbreaks, such as the coronavirus disease 2019 (COVID-19) outbreak, and associated restrictions to prevent spread can lead to negative psychological outcomes, including loneliness, depression, and anxiety…
- Conditions
- Scleroderma, Scleroderma, Systemic, Systemic Sclerosis
- Trial name
- SPIN-CHAT (NCT04335279)
- Testing
- SPIN-CHAT Program
- Where
- Canada
- Volunteers
- 172 people
- Sponsor
- Lady Davis Institute
Pulmonary Arterial Hypertension, Systemic Sclerosis
Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
Aim: to investigate the role of inflammation and auto-immunity in pulmonary arterial hypertension by using the profile of volatile organic compounds.
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Systemic Lupus
- Trial name
- VOC-PAH (NCT03819777)
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Maastricht University Medical Center
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Systemic Sclerosis Pulmonary, Pulmonary Hypertension
Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement
Progressive SSc is an entity with limited therapeutic alternatives and with asurvival rate of less than 45% in the first 3 to 5 years.
- Conditions
- Systemic Sclerosis Pulmonary, Pulmonary Hypertension, Pulmonary Fibrosis
- Trial name
- NCT04432545
- Testing
- Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly
- Where
- Colombia
- Sponsor
- Universidad de la Sabana
Pulmonary Hypertension
Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) compared to placebo (sugar pill) in the treatment of patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00080457
- Testing
- sitaxsentan sodium
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Encysive Pharmaceuticals